Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Autor: Ustun C; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota., Morgan E; Department of Pathology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts., Moodie EEM; Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Quebec, Canada., Pullarkat S; Department of Pathology, University of California, Los Angeles, California., Yeung C; Fred Hutchinson Cancer Research Center, Seattle, Washington.; University of Washington School of Medicine, Seattle, Washington., Broesby-Olsen S; Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis, Odense, Denmark.; Mastocytosis Center Odense University Hospital, Odense, Denmark., Ohgami R; Department of Pathology, Stanford University, Stanford, California., Kim Y; Department of Pathology, City of Hope National Medical Center, Duarte, California., Sperr W; Division of Hematology & Hemostaseology, Ludwig Boltzmann Cluster Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria., Vestergaard H; Mastocytosis Center Odense University Hospital, Odense, Denmark.; Department of Hematology, Odense University Hospital, Odense, Denmark., Chen D; Department of Pathology, Mayo Clinic, Rochester, Minnesota., Kluin PM; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Dolan M; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota., Mrózek K; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Czuchlewski D; Department of Pathology, University of New Mexico, Albuquerque, New Mexico., Horny HP; Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany., George TI; Department of Pathology, University of New Mexico, Albuquerque, New Mexico.; Department of Pathology, University of Utah, Salt Lake City, Utah., Kristensen TK; Mastocytosis Center Odense University Hospital, Odense, Denmark.; Department of Pathology, Odense University Hospital, Odense, Denmark., Ku NK; Department of Pathology, University of California, Los Angeles, California., Yi CA; Department of Pathology, University of New Mexico, Albuquerque, New Mexico., Møller MB; Mastocytosis Center Odense University Hospital, Odense, Denmark.; Department of Pathology, Odense University Hospital, Odense, Denmark., Marcucci G; Division of Hematology and HCT, City of Hope, Duarte, California., Baughn L; Department of Pathology, Mayo Clinic, Rochester, Minnesota.; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota., Schiefer AI; Department of Pathology, Medical University of Vienna, Vienna, Austria., Hilberink JR; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Pullarkat V; Division of Hematology and HCT, City of Hope, Duarte, California., Shanley R; Biostatistics and Bioinformatics, University of Minnesota, Minneapolis, Minnesota., Kohlschmidt J; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Alliance Statistics and Data Center, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Coulombe J; Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Quebec, Canada., Salhotra A; Division of Hematology and HCT, City of Hope, Duarte, California., Soma L; Fred Hutchinson Cancer Research Center, Seattle, Washington.; University of Washington School of Medicine, Seattle, Washington., Cho C; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, New York, New York., Linden MA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota., Akin C; Department of Pathology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.; Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Michigan., Gotlib J; Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, California., Hoermann G; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria., Hornick J; Department of Pathology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts., Nakamura R; Division of Hematology and HCT, City of Hope, Duarte, California., Deeg J; Fred Hutchinson Cancer Research Center, Seattle, Washington.; University of Washington School of Medicine, Seattle, Washington., Bloomfield CD; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Weisdorf D; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota., Litzow MR; Department of Internal Medicine and Division of Hematology, Mayo Clinic, Rochester, Minnesota., Valent P; Division of Hematology & Hemostaseology, Ludwig Boltzmann Cluster Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria., Huls G; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Perales MA; Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, New York, New York., Borthakur G; Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2018 Sep; Vol. 7 (9), pp. 4447-4455. Date of Electronic Publication: 2018 Aug 16.
DOI: 10.1002/cam4.1733
Abstrakt: Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.
Methods: Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).
Results: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P < 0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P < 0.0001).
Conclusions: I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk I-CBFit score).
(© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje